TimesSquare Mid Cap Growth Strategy Picks Ionis Pharmaceuticals (IONS) on Clinical Momentum

2 hours ago 1

Soumya Eswaran

Thu, July 2, 2026 astatine 8:47 AM CDT 3 min read

TimesSquare Capital Management, an equity concern absorption company, released its "U.S. Mid Cap Growth Strategy" first-quarter 2026 capitalist letter. A transcript of the missive tin be downloaded here. The Strategy fell 7.72% (net) successful the 4th compared to -6.35% for the Russell Midcap Growth Index. In the archetypal quarter, markets navigated geopolitical tensions and economical resilience alongside impermanent planetary tariffs. High lipid prices and proviso concatenation disruptions followed U.S. and Israeli engagement successful Iran, prompting a displacement to safer assets and a reevaluation of proviso chains and vigor dependencies. Central banks maintained dependable policies contempt energy-driven inflation. In this environment, the Strategy remains focused connected disciplined absorption teams with durable competitory advantages. Please reappraisal the Strategy's apical 5 holdings to summation insights into their cardinal selections for 2026.

In its first-quarter 2026 capitalist letter, TimesSquare Capital U.S. Mid Cap Growth Strategy highlighted Ionis Pharmaceuticals, Inc. (NASDAQ:IONS). Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is simply a US based commercial-stage biotechnology company, that develops and provides RNA-targeted medicines. On July 1, 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) closed astatine $79.19 per share, reflecting a marketplace capitalization of $13.09 billion. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted a one-month instrumentality of 5.40%, and its shares gained 84.16% implicit the past 52 weeks.

TimesSquare Capital U.S. Mid Cap Growth Strategy stated the pursuing regarding Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) successful its Q1 2026 capitalist letter:

"Our preferences among Health Care stocks are those companies providing caller therapies for unmet needs that bid premium pricing, oregon specialized work providers. New to the assemblage this 4th was Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a commercial-stage biotechnology institution focused connected neurology and cardiovascular indications. They person respective commercially approved drugs positive a heavy pipeline with important objective proceedings readouts this year."

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 60 hedge money portfolios held Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) astatine the extremity of the archetypal quarter, compared to 62 successful the erstwhile quarter. In Q1 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) reported full revenues of $246 million, an summation of 87% year-over-year. While we admit the imaginable of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article